Eli Lilly has started dosing patients in the world's first trial for a medicine specifically designed to attack SARS-CoV-2, the virus that causes COVID-19.
Sanofi had no sooner announced the departure of David Loew, its head of vaccines, before he surfaced as the new chief executive of French specialty drugmaker Ipsen, taking over
After a long run of trial disappointments, AstraZeneca is celebrating a win for its immuno-oncology combination of Imfinzi plus tremelimumab in advanced liver cancer.
Just three months after acquiring Forty Seven for $4.9 billion, Gilead has reported positive data on magrolimab, the lead drug from the deal, at ASCO 2020.
